Ignite Creation Date:
2024-05-06 @ 3:06 PM
Last Modification Date:
2024-10-26 @ 1:42 PM
Study NCT ID:
NCT04510818
Status:
UNKNOWN
Last Update Posted:
2020-08-14
First Post:
2020-08-10
Brief Title:
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial Cohort 2
Sponsor:
Ruijin Hospital
Organization:
Ruijin Hospital
Organization Data
Organization:
Ruijin Hospital
Class:
OTHER
Study ID:
McCrest-2
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Ruijin Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Jun Zhang
Responsible Party Title:
Chair of Department of Oncology
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Ruijin Hospital
Old Name:
None
Old Organization:
None